AI Drug Discovery Startup Ternary Therapeutics Raises £3.6M

London-based biotech innovator, Ternary Therapeutics, has successfully closed a £3.6 million seed funding round to advance its pioneering artificial intelligence platform. This new capital injection is set to accelerate the development of a novel drug discovery engine designed to engineer a class of therapeutics known as 'molecular glues'. The company, established in 2024, aims to revolutionize how challenging protein targets are addressed in medicine.

The core of Ternary Therapeutics' approach lies in its sophisticated AI platform, which synergizes machine learning algorithms with physics-based molecular modeling and rapid experimental validation. This integrated system is engineered to deliberately design molecular glues, a departure from traditional methods where such compounds were often identified serendipitously. The platform's ability to predict protein interactions and propose precise molecular interventions marks a significant step towards a more systematic and predictable drug discovery process.

Molecular glues represent a promising frontier in pharmaceuticals, offering the potential to target proteins previously deemed 'undruggable'. These molecules work by hijacking the cell's natural machinery to degrade or modify specific target proteins. While the therapeutic potential has been recognized, the challenge has always been the difficulty in designing them with precision. Ternary Therapeutics' AI-driven methodology seeks to overcome this hurdle, treating drug design as an engineering discipline rather than a process of random discovery.

The £3.6 million seed investment was spearheaded by venture capital firm daphni. Significant participation also came from Pace Ventures, the i&i Biotech Fund, and the UK Innovation & Science Seed Fund, which is managed by Future Planet Capital. This strong backing from a consortium of investors underscores the market's confidence in Ternary Therapeutics' innovative strategy and its potential to unlock new therapeutic avenues.

Dr. Chris Tame, co-founder of Ternary Therapeutics, highlighted the transformative nature of their platform. "Molecular glues have been instrumental in some of the most exciting therapeutic advancements of the last decade, yet their discovery has largely been a matter of chance," stated Dr. Tame. "Our platform is designed to fundamentally alter this paradigm by integrating physics-informed AI with high-throughput experimental feedback loops. This allows us to engineer these complex molecules with intention and at scale, moving drug discovery from a trial-and-error endeavor to a predictable engineering challenge."

The broader implications for the pharmaceutical industry are substantial. The ability to systematically design molecular glues could unlock treatments for a wide range of diseases, including cancers and neurodegenerative disorders, where specific protein targets have remained elusive. The success of Ternary Therapeutics in securing this funding positions it as a key player in the burgeoning field of AI-driven drug discovery, a sector projected to see significant growth in the coming years as companies increasingly leverage advanced computational tools to accelerate R&D pipelines.

Cristian Pinto, an investor at daphni, commented on the company's robust approach. "Predictably designing molecular glues is one of the most formidable challenges in modern drug discovery. Ternary Therapeutics has developed a rigorous platform that adeptly combines machine learning, fundamental physics principles, and cutting-edge experimental biology to confront this complexity head-on," Pinto remarked, emphasizing the scientific depth behind the startup's innovative solution.